Next Article in Journal
The Number of Surgical Interventions and Specialists Involved in the Management of Patients with Neurofibromatosis Type I: A 25-Year Analysis
Next Article in Special Issue
Collaborative Approach to Reach Everyone with Familial Hypercholesterolemia: CARE-FH Protocol
Previous Article in Journal
Outcomes of Conversion Surgery for Metastatic Gastric Cancer Compared with In-Front Surgery Plus Palliative Chemotherapy or In-Front Surgery Alone
Previous Article in Special Issue
Conjoint Analysis: A Research Method to Study Patients’ Preferences and Personalize Care
Review

Analyzing Precision Medicine Utilization with Real-World Data: A Scoping Review

1
Center for Translational and Policy Research on Precision Medicine (TRANSPERS), Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA 94143, USA
2
School of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Nina Sperber
J. Pers. Med. 2022, 12(4), 557; https://doi.org/10.3390/jpm12040557
Received: 19 February 2022 / Revised: 25 March 2022 / Accepted: 29 March 2022 / Published: 1 April 2022
(This article belongs to the Special Issue Personalized Medicine: The Future of Health Care)
Precision medicine (PM), specifically genetic-based testing, is currently used in over 140,000 individual tests to inform the clinical management of disease. Though several databases (e.g., the NIH Genetic Testing Registry) demonstrate the availability of these sequencing-based tests, we do not currently understand the extent to which these tests are used. There exists a need to synthesize the body of real-world data (RWD) describing the use of sequencing-based tests to inform their appropriate use. To accomplish this, we performed a scoping review to examine what RWD sources have been used in studies of PM utilization between January 2015 and August 2021 to characterize the use of genome sequencing (GS), exome sequencing (ES), tumor sequencing (TS), next-generation sequencing-based panels (NGS), gene expression profiling (GEP), and pharmacogenomics (PGx) panels. We abstracted variables describing the use of these types of tests and performed a descriptive statistical analysis. We identified 440 articles in our search and included 72 articles in our study. Publications based on registry databases were the most common, followed by studies based on private insurer administrative claims. Slightly more than one-third (38%) used integrated datasets. Two thirds (67%) of the studies focused on the use of tests for oncological clinical applications. We summarize the RWD sources used in peer-reviewed literature on the use of PM. Our findings will help improve future study design by encouraging the use of centralized databases and registries to track the implementation and use of PM. View Full-Text
Keywords: real-world data; precision medicine; registry; utilization; scoping review real-world data; precision medicine; registry; utilization; scoping review
Show Figures

Figure 1

MDPI and ACS Style

Douglas, M.P.; Kumar, A. Analyzing Precision Medicine Utilization with Real-World Data: A Scoping Review. J. Pers. Med. 2022, 12, 557. https://doi.org/10.3390/jpm12040557

AMA Style

Douglas MP, Kumar A. Analyzing Precision Medicine Utilization with Real-World Data: A Scoping Review. Journal of Personalized Medicine. 2022; 12(4):557. https://doi.org/10.3390/jpm12040557

Chicago/Turabian Style

Douglas, Michael P., and Anika Kumar. 2022. "Analyzing Precision Medicine Utilization with Real-World Data: A Scoping Review" Journal of Personalized Medicine 12, no. 4: 557. https://doi.org/10.3390/jpm12040557

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop